Rheumatoid Arthritis

“Disease-related malnutrition is strongly associated with morbidity, disability, short- and long-term mortality, and impaired disease recovery," investigators explained.

P38 mitogen-activated protein kinase (p38 MAPK) inhibitors have been a focal point for inflammatory diseases but the lack of efficacy in treating rheumatoid arthritis led to examination of the MK2 pathway.

New survey data from Europe show how factors of the pandemics impacted long-term rheumatoid arthritis management.

Factors including age and disease activity influenced the selection of JAK inhibitors over biologic disease-modifying antirheumatic drugs for RA patients beginning therapy.

A systematic review and meta-analysis of 30 studies indicates a favorable effect of TNF inhibitors on surrogate markers for CVD risk.

“Despite the multiple benefits offered by physical activity (PA), the proportion of older adults meeting PA guidelines is between 27% to 44%," investigators explained.

When is the right time to taper glucocorticoids and what is the correct approach? Take this quiz to test your knowledge.

Studying quality care markers can help clinicians understand treatment variations and non-adherence in patients with rheumatoid arthritis, which may improve outcomes and decrease financial burdens.

The etanercept biosimilar, YLB113 (Nepexto), maintained a favorable efficacy, safety, and immunogenicity profile through week 96.

In the post-hoc analysis, an association between cumulative local joint swelling and progression of radiographic damage in the same joint was observed in patients with rheumatoid arthritis.

Despite EULAR recommendations encouraging the tapering of glucocorticoids and the rapidly expanding treatment options for patients with rheumatoid arthritis, glucocorticoids are still commonly prescribed to reduce inflammation and manage disease activity.

There has been a rapid uptake of Janus kinase (JAK) inhibitors for the treatment of rheumatoid arthritis. How much do you know about this class of drugs? Test your knowledge with this quiz.

Nehad Soloman, MD; Joy Schechtman, DO; and Robert Levin, MD, share final thoughts and takeaways on the treatment of rheumatoid arthritis in the community setting.

Nehad Soloman, MD; Joy Schechtman, DO; and Robert Levin, MD, discuss barriers to rheumatoid arthritis (RA) treatment selection such as insurance access.

Disease-dependent factors, such as a history of adverse reactions to bio-originators and disease activity, influenced patients' acceptance of switching from a biologic to a biosimilar.

Results of the study, which focused on patient-reported outcomes in addition to clinical measurements, mirror findings from other large-scale studies evaluating the safety and efficacy of biosimilars in patients with rheumatoid arthritis.

Drs Nehad Soloman, Joy Schechtman, and Robert Levine share their thoughts on how MSRC test results impact the treatment selection for patients with RA.

Experts in rheumatology review the molecular signature response classifier (MSRC) test for use in guiding RA treatment selection.

At the 6-month mark, there were no significant differences between the treatment groups regarding composite score-defined remission.

It is well-known that rheumatoid arthritis patients have a heightened risk of cardiovascular events, but how do RA treatments affect this risk? Test your knowledge with this quiz.

Ayman Askari, MD, discusses the recent trends in rheumatoid arthritis, studies presented at the American College of Rheumatology (ACR) Convergence 2022, and the pressing issues that face rheumatologists moving into 2023.

Nehad Soloman, MD, leads a discussion about precision medicine in the treatment arsenal for RA.

Nehad Soloman, MD, Joy Schechtman, DO, and Robert Levine, MD, discuss American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) recommendations regarding appropriate timing when changing therapies in managing RA.

Rheumatology specialists review factors in switching a patient with RA to a different treatment, including timing, efficacy assessment, and barriers.

Nehad Soloman, MD, Joy Schechtman, DO, and Robert Levine, MD, examine potential risks in continuing a patient on an ineffective treatment in RA.